Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

HIV franchise sales offset HCV declines

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
1Q Revenues: $5.3 billion (+4%)
1Q Earnings: $2.0 billion (+28%)
Comments: HIV product sales were $3.6 billion, up 13% primarily driven by higher sales as a result of the continued uptake of Biktarvy. Chronic hepatitis C virus (HCV) product sales were $790 million down 21% primarily due to lower patient starts and competitive dynamics, including a decline in price in U.S. Medicare. Yescarta, which was approved in the U.S. in October 2017 and Europe in August 2018, generated $96 million in sales, up 140%. Other product sales, which include products from Gilead’s chronic hepatitis B virus (HBV), cardiovascular, oncology and other categories, were $696 million, down 7% primarily due to the decline in Ranexa sales after generic entry in the first quarter of 2019.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters